Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says
Publishing timestamp: 2023-12-14 11:22:09
Summary
Midstage trial data shows that Moderna and Merck's experimental cancer vaccine, when used in combination with Merck's Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer by half after three years. The vaccine could potentially receive regulatory approvals and launch in some countries by 2025. The combination also reduced the risk of melanoma spreading to other parts of the body. The companies are also testing the vaccine with Keytruda against other tumor types.
Sentiment: POSITIVE
Keywords: moderna inc, business news, merck & co inc, business, biotechnology, breaking news, health care industry, science, pharmaceuticals, biotech and pharmaceuticals,
Source: https://www.cnbc.com/2023/12/14/moderna-merck-cancer-vaccine-reduces-risk-of-skin-cancer-return.html